Adirondack Trust Co. Has $4.26 Million Holdings in Johnson & Johnson (JNJ)

Adirondack Trust Co. decreased its position in Johnson & Johnson (NYSE:JNJ) by 10.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,203 shares of the company’s stock after selling 3,835 shares during the period. Johnson & Johnson accounts for approximately 3.4% of Adirondack Trust Co.’s investment portfolio, making the stock its 5th largest position. Adirondack Trust Co.’s holdings in Johnson & Johnson were worth $4,260,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Lenox Wealth Advisors Inc. grew its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the last quarter. Lbmc Investment Advisors LLC grew its position in shares of Johnson & Johnson by 0.4% in the 1st quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after buying an additional 14 shares during the last quarter. Stratford Consulting LLC grew its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Stratford Consulting LLC now owns 2,728 shares of the company’s stock valued at $361,000 after buying an additional 16 shares during the last quarter. Iron Financial LLC grew its position in shares of Johnson & Johnson by 0.5% in the 2nd quarter. Iron Financial LLC now owns 3,782 shares of the company’s stock valued at $500,000 after buying an additional 19 shares during the last quarter. Finally, North Point Portfolio Managers Corp OH grew its position in shares of Johnson & Johnson by 0.7% in the 2nd quarter. North Point Portfolio Managers Corp OH now owns 2,923 shares of the company’s stock valued at $387,000 after buying an additional 20 shares during the last quarter. Hedge funds and other institutional investors own 65.90% of the company’s stock.

Johnson & Johnson (NYSE JNJ) traded up $0.71 during midday trading on Tuesday, hitting $139.72. 619,367 shares of the stock were exchanged, compared to its average volume of 5,873,962. Johnson & Johnson has a twelve month low of $109.32 and a twelve month high of $144.35. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $376,059.06, a PE ratio of 19.60, a P/E/G ratio of 2.85 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.68 earnings per share. equities analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.40%. Johnson & Johnson’s payout ratio is 58.33%.

Several research analysts have issued reports on JNJ shares. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 18th. Citigroup began coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 target price for the company. Goldman Sachs Group cut shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and raised their target price for the stock from $125.00 to $130.00 in a research note on Wednesday, September 20th. Finally, Jefferies Group upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the company from $145.00 to $157.00 in a research note on Wednesday, October 11th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $144.59.

ILLEGAL ACTIVITY WARNING: “Adirondack Trust Co. Has $4.26 Million Holdings in Johnson & Johnson (JNJ)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/05/johnson-johnson-jnj-stake-lessened-by-adirondack-trust-co.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply